These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 27197003)

  • 41. The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.
    Berkman AM; Hildebrandt MAT; Landstrom AP
    Clin Genet; 2021 Aug; 100(2):132-143. PubMed ID: 33871046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.
    Wojnowski L; Kulle B; Schirmer M; Schlüter G; Schmidt A; Rosenberger A; Vonhof S; Bickeböller H; Toliat MR; Suk EK; Tzvetkov M; Kruger A; Seifert S; Kloess M; Hahn H; Loeffler M; Nürnberg P; Pfreundschuh M; Trümper L; Brockmöller J; Hasenfuss G
    Circulation; 2005 Dec; 112(24):3754-62. PubMed ID: 16330681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors for anthracycline-associated cardiotoxicity.
    Reinbolt RE; Patel R; Pan X; Timmers CD; Pilarski R; Shapiro CL; Lustberg MB
    Support Care Cancer; 2016 May; 24(5):2173-2180. PubMed ID: 26563179
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.
    Chia PL; Chiang K; Snyder R; Dowling A
    J Oncol Pharm Pract; 2018 Jun; 24(4):264-271. PubMed ID: 29284360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of adverse drug effects: a pharmacogenomic approach.
    Scott EN; Hasbullah JS; Carleton BC; Ross CJD
    Curr Opin Pediatr; 2020 Oct; 32(5):646-653. PubMed ID: 32796162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors.
    Hildebrandt MAT; Reyes M; Wu X; Pu X; Thompson KA; Ma J; Landstrom AP; Morrison AC; Ater JL
    Sci Rep; 2017 Aug; 7(1):9698. PubMed ID: 28851949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review.
    Conway A; McCarthy AL; Lawrence P; Clark RA
    BMC Cancer; 2015 May; 15():366. PubMed ID: 25948399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
    Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
    [No Abstract]   [Full Text] [Related]  

  • 50. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
    de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
    Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
    van Dalen EC; van den Brug M; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
    Smith LA; Cornelius VR; Plummer CJ; Levitt G; Verrill M; Canney P; Jones A
    BMC Cancer; 2010 Jun; 10():337. PubMed ID: 20587042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
    BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
    Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
    J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients.
    Stansfeld A; Radia U; Goggin C; Mahalingam P; Benson C; Napolitano A; Jones RL; Rosen SD; Karavasilis V
    Expert Opin Pharmacother; 2022 Oct; 23(14):1641-1650. PubMed ID: 36102190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemotherapy-related cardiotoxicity: are Australian practitioners missing the point?
    Conyers R; Costello B; La Gerche A; Tripaydonis A; Burns C; Ludlow L; Lange P; Ekert P; Mechinaud F; Cheung M; Martin M; Elliot D
    Intern Med J; 2017 Oct; 47(10):1166-1172. PubMed ID: 28485067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.